Drug Profile
Research programme: cell therapies - ViaCell
Latest Information Update: 06 Apr 2011
Price :
$50
*
At a glance
- Originator ViaCell
- Developer Amgen; ViaCell
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Heart failure; Muscular dystrophies; Stroke